May 23, 2011
After an accelerated review, the European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed Victrelis (boceprevir), Merck's new hepatitis C treatment, and recommended that the European Commission grant marketing approval. The committee said Victrelis should be used in combination with interferon-based treatment in untreated patients with chronic hepatitis C, as well as in patients who had failed on treatment. The action came just a week after the drug was approved by the US Food and Drug Administration.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|Let's Advance the Conversation Among Black Women on HIV and PrEP|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|